Investigation into the usefulness and adverse events of CDDP, 5-FU and dl-Leucovorin (PFL-therapy) for advanced colorectal cancer

Journal of Medical and Dental Sciences

Volumn 49, Issue 2, 2002, Pages 77-84

  Okabe, Satoshi ^a   Ishikawa, Toshiaki ^a   Tanami, Hideaki ^a   Kuwabara, Hiroshi ^a   Fukahara, Toshiaki ^a   Udagawa, Masaru ^a   Ootsukasa, Shunrou ^a   Arai, Takehiro ^a   Maruyama, Shouji ^a   Murase, Naoya ^a   Yamashita, Hironori ^a   Iwai, Takehisa ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

5 FU; Biochemical modulation; CDDP; Colorectal carcinoma; Intensive chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; PFL PROTOCOL;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; DIARRHEA; DRUG ADMINISTRATION; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; PATHOLOGY; SKIN DISEASE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KARNOFSKY PERFORMANCE STATUS; LEUCOVORIN; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; SKIN DISEASES; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 23744449633     PISSN: 13428810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990; 8: 1466-1475.
2. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63: 1026-1030.
3. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989; 63: 1036-1044.
4. O'Connell MJ, Gunderson LL. Adjuvant therapy for adenocarcinoma of the rectum. World J Surg 1992; 16: 510-515.
5. Chu E, Grem JL, Johnston PG, et al. New concepts for the development and use of antifolates. Stem Cells 1996; 14: 41-46.
6. Asato Y, Yoshimi F, Ono H, et al. Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin (in Japanese, English abstract). Gan To Kagaku Ryoho 1999; 26: 945-950.
7. Yang TS, Hsu KC, Chiang JM, et al. A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. Cancer 1999; 85: 1925-1930.
8. Sasaki T, Ota K, Sakata Y, et al. High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group (in Japanese, English abstract). Gan To Kagaku Ryoho 1990; 17: 2361-2368.
9. O'Connell MJ, Moertel CG, Kvols LK, et al. Clinical trial of cis-platin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer. Am J Clin Oncol 1986; 9: 192-195.
10. Scanlon KJ, Safirstein RL, Thies H, et al. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res 1983; 43: 4211-4215.
11. Shirasaka T, Shimamoto Y, Ohshimo H, et al. Mechanism for synergistic antitumor effect in the combination of 5- fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil (in Japanese, English abstract). Gan To Kagaku Ryoho 1991; 18: 403-409.
12. Hirata K, Yamamitsu S, Tsuji A, et al. Biochemical modulation of 5-FU-effect of low dose CDDP (in Japanese, English abstract). Gan To Kagaku Ryoho 1999; 26: 467-475.
13. Saijo N, Sasaki YOhe Y. Combination chemotherapy of 5-fluorouracil plus leucovorin(in Japanese, English abstract). Metabolism 1989; 26: 209-219.
14. Kemeny N, Israel K, Niedzwiecki D, et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cis-platin in patients with metastatic colorectal cancer. J Clin Oncol 1990; 8: 313-318.
15. Crum ED. Effect of cisplatin upon expression of in vivo immune tumor resistance. Cancer Immunol Immunother 1993; 36: 18-24.
16. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
17. Shimosato Y, Oboshi SBaba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinoma. Jpn J Clin Oncol 1971; 1: 19-35.
18. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-257.
19. Karnofsky D, Abelman WCraver L. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-656.
20. Zubrod C, Schneiderman MFrei E. Appraisal of methods for the study of chemotherapy in men: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960; 11: 7-33.
21. Sugano K, Ota K, Taguchi T, et al. Early phase II trial of I-leucovorin and 5-fluorouracil in advanced colorectal cancer. I-Leucovorin and 5-FU Study Group (in Japanese, English abstract). Gan To Kagaku Ryoho 1995; 22: 627-637.
22. Yoshino M, Ota K, Kurihara M, et al. Late phase II trial of high-dose I-leucovorin and 5-fluorouracil in advanced colorectal carcinoma. I-Leucovorin and 5-FU Study Group (Japan Eastern Group) (in Japanese, English abstract). Gan To Kagaku Ryoho 1995; 22: 785-792.
23. Guglielmi A, Aschele C, Grossi F, et al. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. Cytotechnology 1996; 19: 215-219.
24. Scheithauer W, Rosen H, Schiessel R, et al. Treatment of patients with advanced colorectal cancer with cisplatin, 5- fluorouracil, and leucovorin. Cancer 1991; 67: 1294-1298.
25. Scheithauer W, Depisch D, Kornek G, et al. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer 1994; 73: 1562-1568.
26. Shibusawa M, Takata M, Kamiyama G, et al. Dual biochemical modulation therapy using 5-FU, leucovorin and cisplatin on human rectal carcinoma xenografts in nude mouse (in Japanese, English abstract). Gan To Kagaku Ryoho 1996; 23: 1149-1152.
27. Katsumata K, Yamamoto K, Ohno M, et al. Evaluation of chemotherapy in the treatment of advanced colorectal cancer-pilot study of 5-FU by biochemical modulation (in Japanese, English abstract). Gan To Kagaku Ryoho 1996; 23: 459-464.
28. Palmeri S, Russo A, Gebbia V, et al. A phase I-II study on the toxicity and therapeutic efficacy of 5- fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma. J Chemother 1990; 2 Suppl 1: 28-32.
29. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
30. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
31. Takeda A, Nakajima K, Shimada H, et al. Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. J Surg Oncol 1999; 71: 112-116.